新型糖肽类万古霉素合成抑制剂 Van-M-02 在耐万古霉素细菌中的作用机制。
Mode of action of Van-M-02, a novel glycopeptide inhibitor of peptidoglycan synthesis, in vancomycin-resistant bacteria.
机构信息
Discovery Research Laboratories, Shionogi & Co., Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan.
出版信息
Antimicrob Agents Chemother. 2010 Feb;54(2):960-2. doi: 10.1128/AAC.00927-09. Epub 2009 Nov 23.
Abstract
Van-M-02, a novel glycopeptide, was revealed to exert potent activities against Gram-positive bacteria, including vancomycin-resistant enterococci (VRE) and vancomycin-resistant Staphylococcus aureus (VRSA). A crude assay system was then used to study the mode of action of Van-M-02 as a peptidoglycan synthesis model of both vancomycin-susceptible and -resistant strains. The results suggested that Van-M-02 inhibits the synthesis of lipid intermediates irrespective of their termini. This inhibitory activity may contribute to the anti-VRE and anti-VRSA activities observed.
摘要
Van-M-02 是一种新型糖肽，被证实对革兰氏阳性菌具有强大的活性，包括耐万古霉素肠球菌（VRE）和耐万古霉素金黄色葡萄球菌（VRSA）。然后使用粗筛检测系统研究了 Van-M-02 的作用模式，作为万古霉素敏感和耐药菌株的肽聚糖合成模型。结果表明，Van-M-02 抑制脂质中间体的合成，而与它们的末端无关。这种抑制活性可能有助于观察到的抗 VRE 和抗 VRSA 活性。
相似文献
1
Mode of action of Van-M-02, a novel glycopeptide inhibitor of peptidoglycan synthesis, in vancomycin-resistant bacteria.
Antimicrob Agents Chemother. 2010 Feb;54(2):960-2. doi: 10.1128/AAC.00927-09. Epub 2009 Nov 23.
2
Redesign of glycopeptide antibiotics: back to the future.
ACS Chem Biol. 2012 May 18;7(5):797-804. doi: 10.1021/cb300007j. Epub 2012 Feb 21.
3
Vancomycin resistance: occurrence, mechanisms and strategies to combat it.
Expert Opin Ther Targets. 2003 Jun;7(3):311-28. doi: 10.1517/14728222.7.3.311.
4
Eremomycin pyrrolidide: a novel semisynthetic glycopeptide with improved chemotherapeutic properties.
Drug Des Devel Ther. 2018 Sep 10;12:2875-2885. doi: 10.2147/DDDT.S173923. eCollection 2018.
5
Structure diversification of vancomycin through peptide-catalyzed, site-selective lipidation: a catalysis-based approach to combat glycopeptide-resistant pathogens.
J Med Chem. 2015 Mar 12;58(5):2367-77. doi: 10.1021/jm501872s. Epub 2015 Feb 24.
6
Opposite effect of vancomycin and D-Cycloserine combination in both vancomycin resistant Staphylococcus aureus and enterococci.
FEMS Microbiol Lett. 2020 Apr 1;367(8). doi: 10.1093/femsle/fnaa062.
7
Synergism between beta-lactams and glycopeptides against VanA-type methicillin-resistant Staphylococcus aureus and heterologous expression of the vanA operon.
Antimicrob Agents Chemother. 2006 Nov;50(11):3622-30. doi: 10.1128/AAC.00410-06. Epub 2006 Sep 5.
8
Maxamycins: Durable Antibiotics Derived by Rational Redesign of Vancomycin.
Acc Chem Res. 2020 Nov 17;53(11):2587-2599. doi: 10.1021/acs.accounts.0c00569. Epub 2020 Nov 2.
9
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.
10
Molecular modeling of Gram-positive bacteria peptidoglycan layer, selected glycopeptide antibiotics and vancomycin derivatives modified with sugar moieties.
Carbohydr Res. 2014 May 7;389:154-64. doi: 10.1016/j.carres.2014.02.002. Epub 2014 Feb 12.
引用本文的文献
1
Deciphering the mode of action of cell wall-inhibiting antibiotics using metabolic labeling of growing peptidoglycan in Streptococcus pyogenes.
Sci Rep. 2017 Apr 25;7(1):1129. doi: 10.1038/s41598-017-01267-5.
2
Screening for FtsZ Dimerization Inhibitors Using Fluorescence Cross-Correlation Spectroscopy and Surface Resonance Plasmon Analysis.
PLoS One. 2015 Jul 8;10(7):e0130933. doi: 10.1371/journal.pone.0130933. eCollection 2015.
3
Staphylococcus aureus Penicillin-Binding Protein 2 Can Use Depsi-Lipid II Derived from Vancomycin-Resistant Strains for Cell Wall Synthesis.
Chemistry. 2013 Sep 2;19(36):12104-12. doi: 10.1002/chem.201301074. Epub 2013 Jul 19.
本文引用的文献
1
Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2009 Jun;53(6):2354-9. doi: 10.1128/AAC.01702-08. Epub 2009 Mar 30.
2
Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.
Clin Infect Dis. 2008 Mar 1;46(5):668-74. doi: 10.1086/527392.
3
New antimicrobial agents as therapy for resistant gram-positive cocci.
Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):3-15. doi: 10.1007/s10096-007-0389-y.
4
Synthesis of rigidly-linked vancomycin dimers and their in vivo efficacy against resistant bacteria.
Chem Commun (Camb). 2007 Jan 21(3):251-3. doi: 10.1039/b613319c. Epub 2006 Oct 24.
5
In vitro assembly of a complete, pentaglycine interpeptide bridge containing cell wall precursor (lipid II-Gly5) of Staphylococcus aureus.
Mol Microbiol. 2004 Jul;53(2):675-85. doi: 10.1111/j.1365-2958.2004.04149.x.
6
Acute infection of mice with Smith strain of Staphylococcus aureus.
Science. 1958 Dec 19;128(3338):1574-5. doi: 10.1126/science.128.3338.1574.
7
Staphylococcus aureus resistant to vancomycin--United States, 2002.
MMWR Morb Mortal Wkly Rep. 2002 Jul 5;51(26):565-7.
8
Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2001 Jun;45(6):1823-7. doi: 10.1128/AAC.45.6.1823-1827.2001.
9
Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia.
Emerg Infect Dis. 1999 Jan-Feb;5(1):147-9. doi: 10.3201/eid0501.990118.
10
Expression of a cloned Staphylococcus aureus alpha-hemolysin determinant in Bacillus subtilis and Staphylococcus aureus.
Infect Immun. 1983 Sep;41(3):1112-7. doi: 10.1128/iai.41.3.1112-1117.1983.
Zotero 插件